Data beget progress. Such is the promise and hope of artificial intelligence, particularly machine learning, to match lung cancer patients with their optimal treatments.

In this episode, Dr. Andrea Mazzocchi, Co-founder and CEO of Known Medicine, dissects the art and the science of how profiling biomarkers, epigenetics and the microenvironment may provide the synergy needed to revolutionize the oncologic landscape.